secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001628280-23-041428
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex extends $10M revolving credit line maturity to Nov 2025; interest rate floor raised to 8.25%
--------------------------------------------------------------------------------

- Revolving credit line of up to $10M extended to November 12, 2025; no amounts outstanding as of filing.
- Interest rate changed to greater of 8.25% or Prime plus 1%; additional 5% during default event.
- Amendment requires maintaining at least 75% of consolidated cash at Western Alliance Bank starting Jan 31, 2024.
- $50,000 renewal fee paid; share repurchases limited to $2.5M aggregate during the term.
- Quick ratio covenant of 1.15:1.00 added to qualify for streamlined reporting period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/0001628280-23-041428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/cdxc-20231208.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-041428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer